Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for various extracellular matrices, have repeatedly been linked to being important initiators and promoters of ovarian cancer growth and progression. Aggressive ovarian tumors exhibit significantly elevated levels of several RGD-based integrin family members, including integrins 5-1 and v3 or v5. These adhesion receptors appear to encourage cell adhesion, survival, motility, and invasion during the development of an ovarian tumor or the spread of its metastatic disease. Notably, the activation of FAK and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways, is crucial for the functions of these integrins.

Transmembrane proteins called integrins serve as important receptors for cell-extracellular matrix (ECM) and cell-cell adhesion.These molecules can be modified, and the v integrin family in particular, has shown to have significant effects on fibrosis in a variety of organs and disease states. According to numerous studies, the latent transforming growth factor (TGF)- is activated by the integrins v3, v5, v6, and v8 in pre-clinical fibrosis models, modulating the fibrotic process.

One of the 18 different types of subunits that are known to exist and one of the eight different types of subunits that are known to exist are typically non-covalently paired to form each integrin. There are currently 24 different heterodimers in total. The fact that the v subunit can form heterodimers with the 1, 3, 5, 6 or 8 subunits and that the 1 subunit can associate with a wide variety of subunits from 1 to 11 shows that not all theoretically possible and subunit pairs form. It's intriguing to note that a variety of v integrins appear to share a common function in TGF- activation.

Integrin related products

Structure Cat No. Product Name CAS No. Product Description
V77367 (R/S)-Alicaforsen ((R/S)-ISIS-2302)
V1598 A-205804 251992-66-2 A-205804 (A205804; A 205804) is a novel selective inhibitor of E-selectin and intercellular adhesion molecule-1 (ICAM-1) expression (IC50 = 20 nM and 25 nM) with potential anticancer activity.
V3083 A286982 280749-17-9 A-286982 isa potent inhibitor of the LFA-1/ICAM-1 interaction with IC50of 44 nM in an LFA-1/ICAM-1 binding assay.
V52457 Abituzumab (EMD 525797; DI17E6) 1105038-73-0
V56051 Abrilumab 1342290-43-0
V56044 Alicaforsen sodium (ISIS-2302 sodium) 331257-52-4
V78124 Arg-Gly-Asp-Ser TFA (RGDS peptide TFA; Fibronectin tetrapeptide TFA)
V56048 ATL 1102 (ISIS-107248) 350263-41-1
V78147 ATL 1102 sodium (ISIS-107248 sodium)
V2794 ATN-161 (Ac-PHSCN-NH2) 262438-43-7 ATN-161 is a novel and potent small peptide inhibitor of the integrin α5β1, it inhibits the angiogenesis and growth of liver metastases in a murine model.
V0434 ATN-161 TFA 904763-27-5 ATN-161 TFA, the trifluoroacetic acid salt ofATN161, is a novel and potent small peptide inhibitor of the integrin α5β1 with potential anticancer activity.
V52341 Bersanlimab (BI-505) 1987854-08-9
V52889 Bexotegrast (PLN-74809) 2376257-44-0
V78567 BT100 sodium
V77182 BT200
V77177 c(phg-isoDGR-(NMe)k) TFA
V2806 Cilengitide (EMD 121974) 188968-51-6 Cilengitide (also known as EMD 121974, NSC 707544) is a highly potent integrin inhibitor for the αvβ3 receptor and the αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; it showed ~10-fold selectivity against gpIIbIIIa.
V1596 Cilengitide TFA (EMD 121974) 199807-35-7 Cilengitide TFA (also known as EMD 121974;NSC-707544;EMD-85189;D-03497), the trifluoroacetic acid salt of cilengitide, is a highly potent and selective integrin inhibitor for the αvβ3 receptor and the αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; it showed~10-fold selectivity against gpIIbIIIa.
V56045 cRGDfK-thioacetyl ester 393781-65-2
V4970 Cucurbitacin B 6199-67-3 Cucurbitacin B, a naturally occurring triterpene analog and a potential cancer chemotherapeutic agent, could repress cancer cell progression.
Contact Us